Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab

M. E. O'Dwyer; T. Launder; J. M. Rabkin; C. R. Nichols

doi:10.3109/10428190009065842

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab

M. E. O'Dwyer, T. Launder, J. M. Rabkin, C. R. Nichols

Oregon Health and Science University

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

20 Citations (Scopus)

Abstract

A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproferative disorder.

Original language	English
Pages (from-to)	411-419
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	39
Issue number	3-4
DOIs	https://doi.org/10.3109/10428190009065842
Publication status	Published - 2000
Externally published	Yes

Keywords

CD20
EBV
Immunosuppression
Organ
Post transplant lymphoproliferative disorder
Rituximab
Treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428190009065842

Cite this

@article{3c0bc404c990430c89a3e927c796d58c,

title = "Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab",

abstract = "A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproferative disorder.",

keywords = "CD20, EBV, Immunosuppression, Organ, Post transplant lymphoproliferative disorder, Rituximab, Treatment",

author = "O'Dwyer, \{M. E.\} and T. Launder and Rabkin, \{J. M.\} and Nichols, \{C. R.\}",

year = "2000",

doi = "10.3109/10428190009065842",

language = "English",

volume = "39",

pages = "411--419",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "3-4",

}

TY - JOUR

T1 - Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab

AU - O'Dwyer, M. E.

AU - Launder, T.

AU - Rabkin, J. M.

AU - Nichols, C. R.

PY - 2000

Y1 - 2000

N2 - A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproferative disorder.

AB - A 52 year-old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproferative disorder.

KW - CD20

KW - EBV

KW - Immunosuppression

KW - Organ

KW - Post transplant lymphoproliferative disorder

KW - Rituximab

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034488521&partnerID=8YFLogxK

U2 - 10.3109/10428190009065842

DO - 10.3109/10428190009065842

M3 - Article

C2 - 11342323

AN - SCOPUS:0034488521

SN - 1042-8194

VL - 39

SP - 411

EP - 419

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3-4

ER -

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this